CD47 Regulates Bone Mass and Tumor Metastasis to Bone
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
CD47, also called integrin-associated protein, plays a critical role in the innate immune response and is an atypical member of the immunoglobulin superfamily that interacts with and activates β3 integrins. β3 integrin−/− mice have defective platelet and osteoclast function and are protected from bone metastasis. The role of CD47 in skeletal homeostasis and bone metastasis has not been described. CD47−/− mice had increased bone mass and defective osteoclast function in vivo. Although the number of functional osteoclasts formed by differentiating CD47−/− bone marrow macrophages was decreased, high doses of RANKL rescued differentiation and function of CD47−/− osteoclasts ex vivo and rescued the osteoclast defect in CD47−/− mice. Inhibition of nitric oxide (NO) synthase, which is expressed at higher levels in CD47−/− osteoclasts, also rescued the osteoclast defect in CD47−/− cells. We then examined the consequences of this osteoclast defect in bone metastasis. In a model of tumor metastasis to bone, bone tumor burden was decreased in the CD47−/− mice compared with wild-type (WT) controls, with no decrease in s.c. tumor growth in CD47−/− mice. There was decreased tumor-associated bone destruction in the CD47−/− mice compared with WT controls, consistent with a defect in osteoclast function that was not rescued by the presence of tumor. Our data show that CD47 regulates osteoclastogenesis, in part, via regulation of NO production, and its disruption leads to a decrease in tumor bone metastasis. CD47 is a novel therapeutic target to strengthen bone mass and diminish metastatic tumor growth in bone. [Cancer Res 2009;69(7):3196–204]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vignery, A. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051123 · Cited by 232
Isenberg, J. S., Romeo, M. J., Yu, C., Yu, C. K., Nghiem, K., Monsale, J., Rick, M. E., Wink, D. A., Frazier, W. A., & Roberts, D. D. (2008) · Blood · doi:10.1182/blood-2007-06-098392 · Cited by 205
Self-citation
Cited by
The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications
Chao, M. P., Weissman, I. L., & Majeti, R. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.01.010 · Cited by 649
Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
Zhang, W., Huang, Q., Xiao, W., Zhao, Y., Pi, J., Xu, H., Zhao, H., Xu, J., Evans, C. E., & Jin, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00018 · Cited by 353
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
Saltarella, I., Desantis, V., Melaccio, A., Solimando, A. G., Lamanuzzi, A., Ria, R., Storlazzi, C. T., Mariggiò, M. A., Vacca, A., & Frassanito, M. A. (2020) · Cells · doi:10.3390/cells9010167 · Cited by 127
“CD47 is expressed at low levels on normal plasma cells, while it is overexpressed on MM cells [70].”
BackgroundThe origins and formation of bone-resorbing osteoclasts
Elson, A., Anuj, A., Barnea-Zohar, M., & Reuven, N. (2022) · Bone · doi:10.1016/j.bone.2022.116538 · Cited by 95
CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models
Xu, J.-F., Pan, X.-H., Zhang, S.-J., Zhao, C., Qiu, B.-S., Gu, H.-F., Hong, J.-F., Cao, L., Chen, Y., Xia, B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4282 · Cited by 88
“Furthermore, patients with osteosarcoma tumors that had higher CD47 expression fared poorly [9, 10].”
Background
Metadata
- Authors
- Uluçkan, O., Becker, S. N., Deng, H., Zou, W., Prior, J. L., Piwnica-Worms, D., Frazier, W. A., & Weilbaecher, K. N.
- Venue
- Cancer Research
- Published
- 2009-04-01
- Volume
- 69
- Issue
- 7
- Pages
- 3196-3204
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2167798168
- Cited by
- 87
- References
- 2
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD47 Regulates Bone Mass and Tumor Metastasis to Bone. https://app.cochat.ai/papers/10.1158/0008-5472.can-08-3358
- The paper
- Uluçkan, O., Becker, S. N., Deng, H., Zou, W., Prior, J. L., Piwnica-Worms, D., Frazier, W. A., & Weilbaecher, K. N. (2009). CD47 Regulates Bone Mass and Tumor Metastasis to Bone. Cancer Research. https://doi.org/10.1158/0008-5472.can-08-3358
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.